Reconstruction of H3N2 influenza virus based virosome in-vitro
-
Asghar Abdoli
,
Hoorieh Soleimanjahi
,
Masoumeh-Tavassoti Kheiri
,
Abbas Jamali
,
Hesam Sohani
,
Mohsen Abdoli
,
Hamid Reza Rahmatollahi
Abstract
Background and Objectives: Virosomes are Virus Like Particles (VLP) assembled in-vitro. Influenza virosomes maintain the cell binding and membrane fusion activity of the wild type virus but are devoid of viral genetic material or internal proteins. Influenza virosomes mimic the natural antigen presentation route of the influenza virus.
Materials and Methods: Virosomes were prepared by membrane solubilization and reconstitution. Briefly, the Madine- Darby Canine kidney (MDCK) cell line was cultivated on microcarrier beads inoculated with influenza virus strain A/X-47 (H3N2). The culture medium was harvested and clarified. Subsequently, virus was concentrated and purified by ultrafiltration and ultracentrifugation. The purified viral membrane was dissolved by adding 375 μl of 200 mM 1, 2-dicaproyl-sn-glycero-3-phosphocholine (DCPC) in HEPES-buffered saline (HBS). Nucleocapsid was removed by ultracentrifugation. The supernatant consisting of phospholipids and glycoproteins of the influenza virus was reconstituted by removal of DCPC using overnight dialysis against Hank’s Buffered Saline (HBS) solution at 4°C. After dialysis, crude virosome preparation was layered over a discontinuous sucrose gradient in order to separate non-incorporated material from the reconstituted virus membranes.
Results: The virosome harvested from the boundary of the two sucrose layers successfully was identified by the Hemagglutination assay and western blotting.
Conclusion: Use of a dialyzable short-chain phospholipid (DCPC) is an efficient procedure for solubilization and reconstitu- tion of influenza virus virosomes and has not caused structural changes in a major envelope glycoprotein (hemagglutinin protein) on the surface of virosome.
Almeida JD, Edwards DC, Brand CM, Heath TD.Formation of virosomes from influenza subunits and liposomes. Lancet 1975; 306(7941): 899-901.
Stegmann T, Morselt H, Booy FP, Van Breemen J, Scherphof G, Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO 1987; 6: 2651.
Jonge JM. Reconstituted viral envelopes as delivery vehicles for nucleic acids. 2007.
Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, et al. The virosome concept for influenza vaccines. Vaccine 2005; 23: S26-S38.
Nussbaum O, Lapidot M, Loyter A. Reconstitution of functional influenza virus envelopes and fusion with membranes and liposomes lacking virus receptors. J Virol 1987; 61: 2245-52.
Bungener L, de Mare A, de Vries-Idema J, Sehr P, van der Zee A, Wilschut J, et al. A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease. Antivi Ther 2006; 11: 717.
Wilschut J. Influenza vaccines: the virosome concept.Immunology letters 2009; 122: 118-121.
Bron R, Ortiz A, Dijkstra J, Stegmann T, Wilschut J. [23] Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes). Methods Enzymol 1993; 220: 313-331.
Genzel Y, Behrendt I, König S, Sann H, Reichl U.
Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine 2004; 22: 2202-2208.
Abbasian F, Tabatabaie H, Sarijloo M, Shahmahmoodi S, Yousefi A, Saberbaghi T et al. A comparative analysis of routine techniques: Reverse transcriptase polymerase chain reaction (RT-PCR) and five cell lines for detection of enteroviruses in stool specimens. Iran J Microbiol 2011; 3: 75-79 .
Noori M, Ghorbani S, Jamali A, Shenagari M, Hashemi H, Saghiri R, et al. Construction of Influenza A/H1N1Virosomal Nanobioparticles. Iran J Virol 2012; 5: 13-18.
de Jonge J, Schoen P, terveer W, Stegmann T, Wilschut J, Huckriede A. Use of a dialyzable short- chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes. Biochim Biophys Acta 2006; 1758: 527-536.
Wilschut J, de Jonge J, Huckriede A, Amorij JP, Hinrichs WLJ, Frijlink HW. Preservation of influenza virosome structure and function during freeze-drying and storage. J Liposome Res 2007; 17: 173-182.
Kistner O, Barrett P, Mundt W, Reiter M, Schober- Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998; 16: 960-968.
Alizadeh E, Kheiri M, Bashar R, Tabatabaeian M, Hosseini SM. Avian Influenza (H9N2) among poultry workers in Iran. Iran J Microbiol 2009; 1: 3-6.
Yousefi A, Fotouhi F, Hosseinzadeh S, Kheiri M, Farahmand B, Montazeri S, et al. Expression of antigenic determinants of the haemagglutinin large subunit of novel influenza virus in insect cells. Folia Biologica (Praha) 2012; 58: 151-156.
Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in influenza virus particles. PLoS Pathog 2008; 4: 1-13.
Zamparo E, Little D. Immunogenicity and effectiveness of virosomal adjuvanted vaccines against influenza: a brief review of their utility in the elderly population. J Prev Med Hyg 2011; 52: 116.
Gasparini R, Lai P. Utility of virosomal adjuvated influenza vaccines: a review of the literature. J Prev Med Hyg 2010; 51: 1-6.
Glück R, Mischler R, Finkel B, Que J, Cryz S, Scarpa B.Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994; 344(8916): 160-163.
De Bruijn I, Nauta J, Gerez L, Palache A. The virosomal influenza vaccine Invivac: Immunogenicity and tolerability compared to an adjuvanted influenza vaccine Fluad in elderly subjects. Vaccine 2006; 24:6629-6631.
Felnerova D, Viret JF, Glück R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004; 15: 518-529.
Herzog C, Hartmann K, Künzi V, Kürsteiner O, Mischler R, Lazar H, et al. Eleven years of Inflexal virosomal adjuvanted influenza vaccine. Vaccine 2009; 27: 4381-4387.
D’Acremont V, Herzog C, Genton B. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J Travel Med 2006; 13: 78-83.
Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, et al. A randomized placebo- controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS One 2007; 2: 1-9.
Liu X, Siegrist S, Amacker M, Zurbriggen R, Pluschke G, Seeberger PH. Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate. ACS Chem Biol 2006; 1: 161-164.
de Jonge J, Holtrop M, Wilschut J, Huckriede A.Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther 2005; 13: 400-411.
| Files | ||
| Issue | Vol 5 No 2 (2013) | |
| Section | Articles | |
| Keywords | ||
| Influenza virus Reconstruction Virosomes | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
